Pharmaceuticals and Drug Development

  1. Pharmaceuticals and Drug Development

Groundbreaking treatment for Alcohol Use Disorder shown to halve alcohol consumption amongst heavy drinkers in three months at phase II: a new hope for patients

Orléans, France, 6 November 2023. Kinnov Therapeutics’ phase II study for its lead compound KT-110 has shown that the treatment can halve alcohol consumption amongst heavy drinkers in three months.    The multi-centre, randomised, double-blind, placebo-controlled Phase II clinical trial included 154 patients suffering from severe alcoholism and was conducted in 34 investigating centres across […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

Pacira Announces FDA Approval of Expanded Exparel Label to Include Two Additional Nerve Block Indications

Exparel is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures TAMPA, […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

Treatment for: Anemia Associated with Chronic Renal Failure Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney […]
Written by
Earlier Onset of A-Fib Linked to Risk of Developing All-Cause Dementia
  1. Pharmaceuticals and Drug Development

Earlier Onset of A-Fib Linked to Risk of Developing All-Cause Dementia

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 10, 2023. By Elana Gotkine HealthDay Reporter THURSDAY, Nov. 9, 2023 — Earlier onset of atrial fibrillation (AF) is associated with increased risk of developing all-cause dementia, vascular dementia (VD), and Alzheimer disease (AD), according to a study published online Nov. 8 in JAMA Network […]
Written by
  1. Pharmaceuticals and Drug Development

First wireless map of worm’s nervous system revealed

This huge step forward in understanding how neurons communicate through extremely short proteins called neuropeptides will help scientists understand how our emotions and mental states are controlled, as well as widespread neuropsychiatric conditions like eating disorders, OCD and PSTD.   The map, which details 31,479 neuropeptide interactions between the worm’s 302 neurons, shows where each neuropeptide, […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

FDA Approves Ixchiq (Chikungunya Vaccine, Live) for the Prevention of Disease Caused by Chikungunya Virus

FDA Approves Ixchiq (Chikungunya Vaccine, Live) for the Prevention of Disease Caused by Chikungunya Virus Saint-Herblain (France), November 10, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has approved Ixchiq®, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

Treatment for: WHIM Syndrome X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) –X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the United States Food and Drug […]
Written by
One-Day Induction of XR Buprenorphine Feasible for Fentanyl Use in OUD
  1. Pharmaceuticals and Drug Development

One-Day Induction of XR Buprenorphine Feasible for Fentanyl Use in OUD

Medically reviewed by Drugs.com. By Elana Gotkine HealthDay Reporter WEDNESDAY, Nov. 8, 2023 — For individuals with opioid use disorder (OUD) using fentanyl, a one-day induction of extended‐release buprenorphine is a feasible treatment approach, according to a study published online Nov. 8 in the American Journal on Addiction. John J. Mariani, M.D., from the New […]
Written by
  1. Pharmaceuticals and Drug Development

Cancer Research UK and the KWF Dutch Cancer Society enter partnership to bring multiple drugs into clinical development

Under the partnership, KWF intends to provide funding to enable the development of select early phase clinical programmes* through Cancer Research UK’s Centre for Drug Development (CDD). Cancer Research UK’s CDD will be utilising its 30 years of experience in ushering first-in-class and best-in-class therapeutics through the clinic to sponsor and manage KWF-supported trials as […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

FDA Approves Zituvimet (sitagliptin and metformin hydrochloride) to Treat Adult Patients With Type 2 Diabetes Mellitus

FDA Approves Zituvimet (sitagliptin and metformin hydrochloride) to Treat Adult Patients With Type 2 Diabetes Mellitus November 06, 2023, Ahmedabad, India — Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Zituvimet (Sitagliptin and Metformin hydrochloride) […]
Written by

Good Reads

5 biotech companies making waves in Wales in 2025

5 biotech companies making waves in Wales in 2025

Newsletter Signup – Under Article / In Page “*” indicates required fields Famous for its rugged coastline and scenic mountains, Wales is also home to a thriving life science industry. Supported by science parks, med-tech companies, and universities, the country has opened up avenues for a budding biotech sector, particularly for the development of startups. […]
Written by

Highlights From MR2025 – State of the Planet

In mid-June, over 400 academics, policymakers and practitioners attended MR2025: Mobility, Adaptation, and Wellbeing in a Changing Climate, hosted by the Columbia Climate School in partnership with the Global Centre for Climate Mobility and the Tamer Institute for Social Enterprise and Climate Change. Since its inception in 2019, the conference has convened every two years […]
Written by

Worlwide

5 biotech companies making waves in Wales in 2025

5 biotech companies making waves in Wales in 2025

Newsletter Signup – Under Article / In Page “*” indicates required fields Famous for its rugged coastline and scenic mountains, Wales is also home to a thriving life science industry. Supported by science parks, med-tech companies, and universities, the country has opened up avenues for a budding biotech sector, particularly for the development of startups. […]
Written by

Highlights From MR2025 – State of the Planet

In mid-June, over 400 academics, policymakers and practitioners attended MR2025: Mobility, Adaptation, and Wellbeing in a Changing Climate, hosted by the Columbia Climate School in partnership with the Global Centre for Climate Mobility and the Tamer Institute for Social Enterprise and Climate Change. Since its inception in 2019, the conference has convened every two years […]
Written by
Scientists reprogram ant behavior using brain molecules

Scientists reprogram ant behavior using brain molecules

From the bright lights of cities that don’t sleep — where people hustle and bustle through the night to keep subways, servers, and supply chains alive — to the whisper-dark understory of tropical forests where ants hum in syncopated lines, the planet’s most intricate societies hinge on round-the-clock cooperation and finely tuned roles. Within Atta […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.